• Regentis Biomaterials entered a four-year exclusive distribution agreement with AMI Medical Technologies to commercialize GelrinC in Israel.
• The knee cartilage repair implant already has regulatory approval from Israel's Ministry of Health.
• The agreement includes minimum purchase requirements, with initial revenue contributions expected in 2027.
• The partners will seek reimbursement coverage from Israeli health maintenance organizations to expand patient access.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Regentis Biomaterials Ltd. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 202611090900ACCESSWRNAPR_____1248774) on November 09, 2026, and is solely responsible for the information contained therein.